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PotencyThe Aryl hydrocarbon receptor (AhR) binds a variety of chlorinated and brominated dioxins, furans and biphe-
nyls. Mixed halogenated variants have been recently identiﬁed in food at signiﬁcant levels but full characterisa-
tion requires potency data in order to gauge their impact on risk assessment. Rat H4IIE and human MCF-7 cells
were treated with various mixed halogenated ligands. Antagonist properties were measured by treating cells
with various concentrations of TCDD in the presence of EC25 of the putative antagonist. Measurement of
CYP1A1 RNAwas used to quantify the potency of agonism and antagonism. The PXDDswere found to be slightly
less potent than the corresponding fully chlorinated congenerswith the exception of 2-B,3,7,8-TriCDDwhichwas
2-fold more potent than TCDD. PXDFs and non-ortho-PXBs were found to bemore potent than their chlorinated
congeners whilst several mono-ortho-substituted PXBs were shown to have partial agonistic properties. REPs
were produced for a range of mixed halogenated AhR-activating ligands providing a more accurate estimation
of potency for risk assessment. Several environmentally abundant biphenyls were shown to be antagonists
and reduce the ability of TCDD to induce CYP1A1. The demonstration of antagonism for AhR ligands represents
a challenge for existing REP risk assessment schemes for AhR ligands.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY 3.0 license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
The Aryl hydrocarbon receptor (AhR) binds awide range of structur-
ally diverse compounds such as dibenzo-p-dioxins, dibenzofurans and
biphenyls (Denison and Nagy, 2003). These AhR ligands, whether chlo-
rinated, brominated or a mixture of both, all undergo the same mecha-
nism of action by activating the AhR. Activation of the AhR leads to the
induction of a battery of xenobiotic enzymes such as cytochrome
P4501A1 (CYP1A1; Behnisch et al., 2001; Schmidt et al., 1996; Vanden
Heuvel et al., 1994). Thusmeasurement of CYP1A1 expression is awide-
ly known and accepted method of determining AhR activation. Activa-
tion of the AhR is generally required to instigate the toxic effects of
AhR agonists, as demonstrated in AhR-null mice, which are resistant
to the acute toxicity of TCDD (Gonzalez and Fernandez-Salguero,
1998; Lin et al., 2002; Stohs andHassoun, 2011). Amore detailed review
of AhR activation can be found elsewhere (Denison et al., 2011).
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is one of the most po-
tent and certainly the best characterised of the AhR ligands. TCDD isUniversity Park, University of
llor).
. This is an open access article underused as a reference compound when estimating the relative estimated
potency (REP), a measure of toxic strength in comparison to TCDD, for
other AhR agonists. The most potent polychlorinated dibenzo-p-dioxins
(PCDDs), polychlorinated dibenzonfuran (PCDFs) and polychlorinated
biphenyls (PCBs) feature in the World Health Organisation's (WHO)
evaluation of toxic equivalency factors (TEFs) of dioxin-like compounds
(European Commission, 2011; Haws et al., 2006; van den Berg et al.,
2006). The TEF values established by the WHO consortium were based
on relative effect potency (REP) values derived from a meta-analysis of
previous potency data (Haws et al., 2006). The TEFs are used to estimate
the total toxic equivalency (TEQ) of a mixture of compounds in an addi-
tive fashion by combining the TEF of each compoundwith the concentra-
tion of the compoundwithin themixture (van den Berg et al., 2006). The
dataset contains the potent but less abundant TCDD (TEF = 1) and PCB
126 (TEF = 0.1) and the more environmentally abundant but consider-
ably less potent mono-ortho-substituted PCBs (TEF = 0.00003).
A great deal of research has been conducted on chlorinated dibenzo-
p-dioxins, dibenzofurans (PCDD/Fs) and biphenyls (PCBs), and a more
limited amount on their brominated analogues (PBDD/Fs, PBBs), with
regard to their toxicity and occurrence in the environment and in
food. However little is known about mixed (chlorinated and brominat-
ed) halogenated dibenzo-p-dioxins (PXDDs), dibenzofurans (PXDFs)the CC BY 3.0 license (http://creativecommons.org/licenses/by/3.0/).
Table 1
Structures of themixed halogenated dibenzodioxins (PXDDs), dibenzofurans (PXDFs) and
biphenyls (PXBs) used in this study.
Dioxins
2-B-7,8-DiCDD — R1 = H; R2 = Br; R3 = H; R4 = Cl; R5 = Cl
2,3,7-TriBDD— R1 = H; R2 = Cl; R3 = Cl; R4 = Br; R5 = H
2,3,7,8-TetraCDD— R1 = H; R2 = Cl; R3 = Cl; R4 = Cl; R5 = Cl
2-B,3,7,8-TriCDD— R1 = H; R2 = Br; R3 = Cl; R4 = Cl; R5 = Cl
2,3-DiB,7,8-DiCDD— R1 = H; R2 = Br; R3 = Br; R4 = Cl; R5 = Cl
1-B,2,3,7,8-TetraCDD— R1 = Br; R2 = Cl; R3 = Cl; R4 = Cl; R5 = Cl
2-B,1,3,7,8-TetraCDD— R1 = Cl; R2 = Br; R3 = Cl; R4 = Cl; R5 = Cl
Furans
2,7,8-TriBDF— R1 = H; R2 = Br; R3 = H; R4 = H; R5 = H; R6 = Br; R7 = Br
2-B,7,8-DiCDF— R1 = H; R2 = Br; R3 = H; R4 = H; R5 = H; R6 = Cl; R7 = Cl
2,3,7,8-TetraCDF— R1 = H; R2 = Cl; R3 = Cl; R4 = H; R5 = H; R6 = Cl; R7 = Cl
3-B,2,7,8-TriCDF— R1 = H; R2 = Cl; R3 = Br; R4 = H; R5 = H; R6 = Cl; R7 = Cl
2,3-DiB,7,8-DiCDF— R1 = H; R2 = Br; R3 = Br; R4 = H; R5 = H; R6 = Cl; R7 = Cl
2-B,6,7,8-TriCDF— R1 = H; R2 = Br; R3 = H; R4 = H; R5 = Cl; R6 = Cl; R7 = Cl
2,3,4,7,8-PentaCDF— R1 = H; R2 = Cl; R3 = Cl; R4 = Cl; R5 = H; R6 = Cl; R7 = Cl
4-B,2,3,7,8-TetraCDF— R1 = H; R2 = Cl; R3 = Cl; R4 = Br; R5 = H; R6 = Cl; R7 = Cl
1-B,2,3,7,8-TetraCDF— R1 = Br; R2 = Cl; R3 = Cl; R4 = H; R5 = H; R6 = Cl; R7 = Cl
1,3,DiB,2,7,8-TriCDF — R1 = Br; R2 = Cl; R3 = Br; R4 = H; R5 = H; R6 = Cl; R7 = Cl
Biphenyls
3,3′,4,4′,5-PentaCB (PCB 126)— R1 = H; R2 = Cl; R3 = Cl; R4 = Cl; R5 = Cl; R6 = Cl
4′-B,3,3′,4,5-TetraCB (PXB 126B)— R1 = Hl; R2 = Cl; R3 = Cl; R4 = Cl; R5 = Br;
R6 = Cl
3′,4′-DiB,3,4,5-TriCB (PXB 126H)— R1 = H; R2 = Cl; R3 = Cl; R4 = Cl; R5 = Br;
R6 = Br
3′,4′,5-TriB,3,4-DiCB (PXB 126V)— R1 = H; R2 = Br; R3 = Cl; R4 = Br; R5 = Br;
R6 = Br
3,3′,4,4′,5-PentaBB (PBB 126)— R1 = H; R2 = Br; R3 = Br; R4 = Br; R5 = Br; R6 = Br
2,3,3′,4,4′-PentaCB (PCB 105)— R1 = Cl; R2 = H; R3 = Cl; R4 = Cl; R5 = Cl; R6 = Cl
4′-B,2,3,3′,4-TetraCB (PXB 105)— R1 = Cl; R2 = H; R3 = Cl; R4 = Cl; R5 = Br; R6 = Cl
2,3′,4,4′,5-PentaCB (PCB 118)— R1 = Cl; R2 = Cl; R3 = Cl; R4 = H; R5 = Cl; R6 = Cl
4′-B,2,3′,4,5-TetraCB (PXB 118)— R1 = Cl; R2 = Cl; R3 = Cl; R4 = H; R5 = Br; R6 = Cl
2,3,3′,4,4′,5-HexaCB (PCB 156)— R1 = Cl; R2 = Cl; R3 = Cl; R4 = Cl; R5 = Cl; R6 = Cl
4′-B,2,3,3′,4,5-PentaCB (PXB 156)— R1 = Cl; R2 = Cl; R3 = Cl; R4 = Cl; R5 = Br;
R6 = Cl
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levels in various food products (Fernandes et al., 2011, 2014). Uninten-
tional formation of these compounds occurs at equivalent levels to chlo-
rinated and brominated congeners (Du et al., 2010) through
combustion processes. Currently PBDD/Fs and PBBs are allocated the
same REP as their chlorinated counterparts (Fernandes et al., 2008;
van den Berg et al., 2013), however, the limited potency work that has
been conducted on PXDD/Fs and PXBs has shown some of them to be
more potent and hence may have a bigger impact on the TEQ of a mix-
ture (Behnisch et al., 2003; Olsman et al., 2007; Samara et al., 2009).
Another issue regarding the TEQ is the putative effect of antagonists
in the estimation of the potency of a mixture. Research in vitro on some
mono-ortho-substituted PCBs has suggested that several of the conge-
ners have both agonistic and antagonistic properties (Clemons et al.,1998; Hestermann et al., 2000). These antagonist effects may reduce
the overall potency of a mixture by inhibiting more potent ‘pure’ ago-
nists from inducing CYP1A1. Three of the most abundant mono-ortho-
substituted PCBs (PCB 105, PCB 118 and PCB 156), have been found in
signiﬁcant quantities in environmental studies (Ahlborg et al., 1992;
Fernandes et al., 2004, 2008; Larebeke et al., 2001; Kalantzi et al.,
2004; Polder et al., 2008; Safe, 1990, 1994) showing the potential to
have a large impact on the ﬁnal TEQ.
Here, we calculate the agonist potency of a range of mixed haloge-
nated PXDDs, PXDFs and PXBs which are currently not included in the
WHO's TEF list. Secondly, we evaluate the putative antagonistic effects
of several of the most abundant mono-ortho-substituted PCBs and
PXBs on the TEQ using a novel method of quantifying the antagonist ef-
fect of various compounds on AhR activation.
2. Materials and methods
2.1. Materials
Dibenzo-p-dioxin, dibenzofuran and biphenyl standards were ob-
tained either from Wellington Laboratories Inc. Ontario, Canada or
fromCambridge Isotope Labs,Mass. USA.Where required, the standards
were solvent exchanged to DMSO and the concentrations veriﬁed using
Gas chromatography/Mass spectroscopy (GC/MS). The chemical names
for the 3,3′,4,4′,5-substituted-mixed halogenated biphenyls have been
published previously (Falandysz et al., 2012). A trace (b0.01%) of either
nonane, toluene or iso-octane may be present but were all shown to
have no effect on cell growth or AhR activation up to concentrations of
0.1%. A summary of the structures of the compounds can be found in
Table 1. Dilution of TCDDwas done in DMSO to 10 μMwhichwas stored
at−20 °C. A 10 mMmono-ortho-substituted PCB top stock was made
by dissolving inDMSO and stored at−20 °C. The remaining compounds
were dissolved in DMSO up to a concentration of 100 μMor 1mM. Once
constituted, all further dilutions weremade using conditionedmedium,
giving a ﬁnal DMSO concentration of b0.2%.
2.2. Conﬁrmation of concentration and absence of contamination
High resolution gas chromatography coupled to high resolution
mass spectrometry (HRGC/HRMS) was used to verify the concentra-
tions used and conﬁrm the absence of contaminants in stock PCB,
PXDD/F and PXB experimental solutions (data not shown). The mass
spectrometer (Autospec Premier Waters) was operated in electron
ionisation (EI) mode at a mass resolution of 10000 for PCBs/PCDD/Fs
and 13,000–15,000 (at 10% peak height) for PXBs, PXDD/Fs with the
mass axis calibrated within a window of 250ppmmass prior to measure-
ment. An acceleration voltage of 7 kV was used in conjunction with an
electron energy of 32–37 eV and a trap current of 450 μA. The two
most intense ions that did not suffer from chemical interference, in
themolecular ion cluster for each analyte, were targeted and were sep-
arated into discrete groups based on the molecular mass range and
chromatographic retention. The full validated methodology has been
described earlier (Fernandes et al., 2004, PCBs; Fernandes et al., 2011,
PXDD/Fs).
2.3. Cell culture
The human MCF-7 cells were a kind gift from Dr Tracey Bradshaw
(Centre for Biomolecular Science, University of Nottingham, UK) and
the rat H4IIE-C3 cells (#85061112) were purchased from the ECACC.
The two cell lines were maintained in minimum essential medium
(MEM; Sigma #M2279) with the addition of 10% foetal bovine serum
(Sigma #F7524), antibiotics (Sigma #G1146) and 1% non-essential
amino acids (Sigma #M7145). Cells were passaged every 3 days and in-
cubated at 37 °C in a 5% CO2 atmosphere.
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Rat H4IIE and humanMCF-7 cells were treatedwith test compounds
to determine their potency. To measure the agonistic properties of the
compounds, cells were seeded in 96-well plates (cell density of 1.5
× 105 cells/well) and treated with the compounds (100 fM 10 μM) for
4 h. Conditioned medium (used medium from untreated cells) was
used to prevent contamination from AhR agonists in the fresh medium
(Adachi et al., 2001). A vehicle only control (no activation) and a 10 nM
TCDD only control (maximum activation) were run alongside the con-
centration–response (C/R) curves to be used for normalisation pur-
poses. Three biological replicates (separate cell samples in individual
wells) were run for each concentration point. The cells were removed
from the plate using 60 μl trypsin (Sigma #T4174) and frozen at−20
°C. The RNA was then puriﬁed using Absolutely RNA® Miniprep Kit
(Stratagene #400800) as per instructions for small sample sizes. cDNA
synthesis was completed using a High capacity RNA-to-cDNA kit (Ap-
plied Biosystems #4387406), samples were incubated for 60 min at 37
°C followed by 5 min at 95 °C using an Eppendorf thermocycler
(Germany). Alongside the samples, a no reverse-transcriptase (No RT)
and a No RNA control were prepared for control purposes. Samples
were stored at−20 °C.
2.5. Antagonism measurement
In addition to the methodology discussed for agonism, to measure
the antagonistic properties, cells were treated with TCDD (100
fM 10 nM) in the presence of the set concentration (~EC25) of the test
compound as identiﬁed in the agonism experiments. Extraction of
RNA and measurement of CYP1A1 RNA was as described for the
agonism experiments. The basis for studying the effect of antagonist
on potency of TCDD for inducing CYP1A1 RNA has been described pre-
viously (Bazzi et al., 2009; Wall et al., 2012a, 2012b).
2.6. qRT-PCR measurement of CYP1A1 RNA
RNA measurement used quantitative real-time PCR to provide a
real-time view of RNA levels. CYP1A1 was measured and normalised
against two reference genes, β-actin and AhR.
Only a single endpoint was used in this study, a common method
used in the literature for REP calculations. A complete master mix was
prepared containing 20 μl Taqman® gene expression master mix (Ap-
plied Biosystems #4369016), CYP1A1, β-actin and AhR primers
(10 μM) and probes (5 μM), 150 ng of cDNA and diethylpyrocarbonate
(DEPC) treated water (made up to 40 μl). The nucleotide sequences
for the primers and probes have been published previously (Wall
et al., 2012b). Previous work has shown that these primers and probes
can be run in the same reaction without interference (Bazzi et al.,
2009; Bell et al., 2007).
The samples were run as two technical replicates (20 μl each) on a
96-well plate. The RNA levels were detected using an Applied
Biosystems 7500 Fast RT-PCR machine with the following protocol: 1
cycle (2 min at 50 °C; 10 min at 95 °C), 40 cycles (20 s at 95 °C; 90 s at
58 °C). Three controls, to check for contamination, were run alongside
each curve; no template control (NTC), No RT and No RNA. The RNA
levels were measured by their Ct values (the cycle at which the ﬂuores-
cence passes a set threshold and is distinguishable from the background
noise) and analysed using qBasePlus v1.3 (Biogazelle). The Ct or copy
number values for CYP1A1were normalised against the values obtained
for β-actin and AhR, and converted into calibrated normalised relative
quantities (CNRQ; Hellemans et al., 2007; Vandesompele et al., 2002).
These values were then further normalised against CYP1A1 RNA levels
from a contemporaneous culture exposed to 10 nM TCDD which was
deﬁned as 100% ormaximal response. The datawas then plotted as con-
centration vs. normalised CYP1A1 RNA (% of maximal response) using
GraphPad Prism 5 which also calculated the EC50s and the 95%conﬁdence intervals (95% CI). It was assumed that all the compounds
would reach 100% response therefore the agonist curves were ﬁtted to
account for this. The C/R curvewas corrected for all the antagonist stud-
ies. The EC50 was calculated as the halfway point between the ~25%
background, due to the antagonist, and the 100% maximal induction.
An unpaired t-test was used to test whether any difference in the
EC50s derived from the antagonism curves was statistically signiﬁcant.
3. Results
3.1. Agonistic properties of mixed halogenated congeners
To ascertain the potency of the selected mixed halogenated com-
pounds and to establishwhether they are as potent than their chlorinat-
ed congeners, this study tested the ability of these compounds to
activate the AhR in H4IIE rat cells, an established methodology for
examining potency (Bazzi et al., 2009; Behnisch et al., 2003; Olsman
et al., 2007; Samara et al., 2009). A key parameter of the experimental
design was the treatment of rat H4IIE cells with the compounds for
4 h, prior to quantitation of CYP1A1 RNA using qRT-PCR (Fig. 1A–E),
since longer treatment periods increase the risk of metabolism of the
chemicals and may result in altered potency estimates (Supplemental
Fig. 1; Bazzi et al., 2009). All of the PXDDs tested were within 20-fold
less potent than TCDD with the exception of 2-B,3,7,8-TriCDD which
was 2-3-fold more potent (Fig. 1A). The PXDFs were also within 20-
fold less potent than TCDD with the exception of 2-B,7,8-DiCDF which
was shown to be ~2000-fold less potent than TCDD (Fig. 1B and C).
The non-ortho-substituted PXBs tested were within 10-fold less potent
than TCDD (Fig. 1D) and the mono-ortho-substituted PXBs were
shown to be at least 5000-fold less potent than TCDD (PCB 156 and
PXB 156; Fig. 1E). Interestingly, the PXDFs and non-ortho-substituted
PXBs were all more potent than their fully chlorinated counterparts.
The results are summarised in Table 2.
Previouswork has shown that certain compounds can have different
potencies in different species, with TCDD ~10-fold less potent in human
MCF-7 cells than in rat H4IIE cells (Wall et al., 2012a, 2012b), in agree-
mentwith other literature (Budinsky et al., 2010; Xuet al., 2000). To test
if there is lower potency in human for a variety of PCDDs and PXBs, and
to relate the data gathered in rats to a humanmodel, several of the com-
poundswere tested in humanMCF-7 cells so that a direct comparison of
potency could be established (Fig. 1F). TCDD and 2-B,3,7,8-TriCDD gave
EC50s in rat H4IIE cells (Fig. 1A) of 47.6 pM (95% CI=36.4 pM–62.2 pM)
and 23.7 pM (95% CI = 15.4 pM–36.6 pM) respectively, whereas in the
human MCF-7 cells, which were treated under the same experimental
conditions, the EC50s were 465 pM (95% CI = 341 pM–633 pM) and
187 pM (95% CI= 111 pM–319 pM) for TCDD and 2-B,3,7,8-TriCDD, re-
spectively. Thus, TCDDwas 10-foldmore potent in ratH4IIE cells than in
human MCF-7 (p b 0.001) whereas 2-B,3,7,8-TriCDD was 8-fold more
potent in rat H4IIE (p b 0.001). Consequently, most of the compounds
were found to be 6- to 30-fold less potent in human MCF-7 compared
to rat H4IIE cells, except for two compounds where it was not possible
to reliably determine the EC50 in human cells. This shows that the
lower potency seen in human MCF7 cells compared with rat H4IIE
cells is a consistent ﬁnding for multiple poly-halogenated dioxins and
biphenyls.
3.2. Antagonist effects of mono-ortho-PCBs
The TEQ system assumes that the agonist properties of each com-
pound can be added together in a mixture to give a cumulative esti-
mate of potency. However, this system does not take into account
antagonists and their potential to reduce the overall potency by
inhibiting other more potent compounds. Therefore we set out to es-
tablish if antagonism is an important consideration for the dioxin
and biphenyl series by quantitatively measuring the putative effects
of antagonists in a mixture with pure agonists. Several mono-ortho-
Fig. 1.Potency comparison of PXDD, PXDF and PXB congeners— Concentration–response relationships for rat H4IIE cells treated for 4 hwith (A) PXDDs, (B) PXDFs (Tri and Tetra substitut-
ed), (C) PXDFs (Penta substituted), (D) Non-ortho-substituted PXBs, (E) Mono-ortho-substituted PXBs and (F) human MCF-7 cells treated with a variety of PXBs. qRT-PCR was used to
measure the level of induction of CYP1A1 and compared against control genes,β-actin and AhR. qBasePlus was used to normalise the datawhichwas plotted using 10 nMTCDD only con-
trol as the maximal response (100%). Each point consists of three biological replicates ± SEM.
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ment, were tested in combination with TCDD using a novel method
of measuring antagonism developed previously (Bazzi et al., 2009).
Rat H4IIE cells were treated for 4 h with various concentrations of
TCDD in the presence of an empirically-determined concentration
of the PXB, the concentration giving a 25% of maximal agonist response
(EC25) (PCB 105, 3 μM; PCB 118, 3 μM; PCB 156, 30 nM; Fig. 1E). PCB 105
and PCB 118 increased the EC50 of TCDD for inducing CYP1A1 by 30-fold
and 10-fold, respectively (p b 0.001) and in combination with the ago-
nist data (Fig. 1E), were both shown to be partial agonists (both agonist
and antagonist properties) in rat H4IIE cells. PCB156 was identiﬁed as a
pure agonist. The effect of a chlorine atom substituted for a bromine
atom (position R5; Table 1) was then investigated in rat H4IIE cells.
PXB 105, PXB 118 and PXB 156 all led to an increase of 200-fold (p b
0.001), 4-fold (p b 0.01) and 100-fold (p b 0.001), respectively, in the
EC50 of TCDD for inducing CYP1A1 RNA (Fig. 2B). In combination with
agonist data (Fig. 1E), all three compounds have agonistic and antago-
nistic behaviour, and are partial agonists. Finally in rat H4IIE cells, the
antagonistic properties of PCB 126, TCDF and PeCDF were tested
(Fig. 2C). The compounds had no effect on the EC50 of TCDD for inducingCYP1A1 RNA. All of the EC50s derived from the antagonist experiments
are summarised in Table 3 and show that the compounds increased the
EC50 of TCDD by up to 200-fold compared with TCDD alone.
Although it is known that there can be species-speciﬁc agonism of
the AhR, it is not known if there is species-speciﬁc antagonism of the
AhR. The antagonist effects of some of these compounds were therefore
tested in a humanMCF-7 cells to see if they have the similar effect of re-
ducing the ability ofmore potent compounds to induce CYP1A1. Human
MCF-7 cells were treated with either the EC25 based on Fig. 1F (300 nM;
PCB 156) or when no responsewas detected in human cells, the highest
tested concentration based on the solubility of the compounds (10 μM;
PCB 105 and PCB 118). A concentration of 10 μMPCB 105or PCB 118had
very little agonistic effect in human cells (Fig. 1F) but both produced a
signiﬁcant antagonist effect on the TCDD response with PCB 105 and
PCB118 having a 35-fold and 25-fold reduction in mixture potency,
respectively (p b 0.001; Fig. 2D). PCB 156 also produced an antagonist
effect in human MCF-7 cells (3-fold reduction; p b 0.01) as well as
being a poor agonist. From this combined data it is possible to conclude
that PCB 105 is a partial agonist in rat H4IIE cells and an antagonist in
human MCF-7 at the concentrations tested, PCB 118 is a partial agonist
Table 2
Summary of REP values calculated in this study and comparison with the literature.
Compound Rat Human 2005 WHO
TEF
Behnisch et al.
(2003)
Olsman et al.
(2007)
Samara et al.
(2009)
EC50 (95% CI) REP EC50 (95% CI) REP
2,3,7-TriBDD 904 pM (710 pM–1.15 nM) 0.052 – – – 0.033 0.081 0.0006
2-B-7,8-DiCDD 1.16 nM (813 pM–1.64 nM) 0.041 – – – – 0.061 –
2,3,7,8-TetraCDD 47.6 pM (36.4 pM–62.2 pM) 1a 465 pM (341 pM–633 pM) 1 1 1 1 1
2-B,3,7,8-TriCDD 23.7 pM (15.4 pM–36.6 pM) 2.01 187 pM (111 pM–317 pM) 2.4847 – 0.67 1.93 0.72
2,3-DiB-7,8-DiCDD 168 pM (138 pM–206 pM) 0.28 – – – 0.86 1.00 0.43
1-B,2,3,7,8-TetraCDD 398 pM (264 pM–599 pM) 0.12 – – – 0.28 – –
2-B,1,3,7,8-TetraCDD 86.4 pM (65.3 pM–114 pM) 0.55 – – – 0.37 1.52 –
2,7,8-TriBDF 2.02 nM (1.10 nM–3.71 nM) 0.024 – – – – 0.00049 –
2-B-7,8-DiCDF 129 nM (90.1 nM–184 nM) 0.00037 – – – – 0.000037 –
2,3,7,8-TetraCDF 413 pM (196 pM–869 pM) 0.12 – – 0.1 0.32 – 0.07
3-B,2,7,8-TriCDF 151 pM (106 pM–214 pM) 0.32 – – – 0.74 – 0.38
2,3-DiB,7,8-DiCDF 80.3 pM (65.0 pM–99.1 pM) 0.59 – – – – – –
2-B,6,7,8-TriCDF 305 pM (214 pM–434 pM) 0.16 – – – – 0.00066 –
2,3,4,7,8-PentaCDF 278 pM (179 pM–433 pM) 0.17 – – 0.3 0.5 – 0.46
4-B,2,3,7,8-TetraCDF 150 pM (86.9 pM–260 pM) 0.32 – – – – – –
1-B,2,3,7,8-TetraCDF 351 pM (275 pM–449 pM) 0.14 – – – – – –
1,3,DiB,2,7,8-TriCDF 214 pM (119 pM–386 pM) 0.22 – – – – – –
2,3,7,8-TetraCDD 28.9 pM (19.9 pM–41.9 pM) 1b – – 1 1 1 1
3,3′,4,4′,5-PentaCB 281 pM (225 pM–352 pM) 0.10 3.81 nM (2.89 nM–5.02 nM) 0.1221 0.1 0.067 – –
4′-B,3,3′,4,5-TetraCB 130 pM (92.2 pM–183 pM) 0.22 947 pM (807 pM–1.11 nM) 0.4908 – – – –
3′,4′-DiB,3,4,5-TriCB 200 pM (78.2 pM–513 pM) 0.14 – – – – – –
3′,4′,5-TriB,3,4-DiCB 72.2 pM (48.4 pM–108 pM) 0.40 – – – – – –
3,3′,4,4,5-PentaBB 622 pM (487 pM–796 pM) 0.046 – – – 0.16 – –
2,3,3′,4,4′-PentaCB 16.0 μM (15.6 μM–16.3 μM) 0.000002 N/Ac b0.00005 0.00003 0.000012 – –
4′-B,2,3,3′,4-TetraCB 2.46 μM (2.10 μM–2.90 μM) 0.00001 – – – – – –
2,3′,4,4′,5-PentaCB 11.8 μM (10.5 μM–13.2 μM) 0.000003 N/Ac b0.00005 0.00003 0.00001 – –
4′-B,2,3′,4,5-TetraCB 775 nM (655 nM–917 nM) 0.00003 – – – – – –
2,3,3′,4,4′,5-HexCB 122 nM (104 nM–144 nM) 0.0002 3.59 μM (2.81 μM–4.59 μM) 0.0001 0.00003 0.0002 – –
4′-B,2,3,3′,4,5-PentaCB 139 nM (95.5 nM–203 nM) 0.0002 – – – – – –
a TCDD value used for dioxin and furan REP estimations.
b TCDD value used for PXB REP estimations.
c Not enough data to calculate an EC50.
Fig. 2. Antagonistic properties of PXBs and PXDFs — Concentration–response relationships for TCDD in the absence and presence of a set concentration of test compound (EC25) in cells
treated for 4 h. Three of the most abundant mono-ortho-substituted PCBs were tested in (A) rat H4IIE or (B) human MCF7 cells. Cells were tested with various concentrations of PCB
105, PCB 118 or PCB 156 for 4 h. (C) Mixed halogenated mono-ortho-substituted PXBs were tested in rat H4IIE cells. (D) The antagonistic properties of several well characterised furans
and a PCB were tested in rat H4IIE cells. qRT-PCRwas used to measure the level of induction of CYP1A1 and compared against control genes, β-actin and AhR. qBasePlus was used to nor-
malise the data which was plotted using 10 nM TCDD only control as the maximal response (100%). All of the results were compared with an antagonist only control (AC). Each point
consists of three biological replicates ± SEM.
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Table 3
Summary of TCDD EC50's in the absence and presence of selected PXB and PXDF
antagonists.
Compound EC50 (95% conﬁdence interval)a Fold decrease
Rat
TCDD 29 pM (20 pM–42 pM)**
+3 μM PCB 105 810 pM (190 pM–3.4 nM)** 30-fold
+1 μM PXB 105 5.6 nM (1.6 nM–19 nM)** 200-fold
+3 μM PCB 118 310 pM (75 pM–1.3 nM)** 10-fold
+300 nM PXB 118 96 pM (46 pM–200 pM)* 3-fold
+30 nM PCB 156 46 pM (25 pM–86 pM) –
+100 nM PXB 156 2.7 nM (170 pM–43 nM)** 100-fold
+100 pM PCB 126 54 pM (27 pM–110 pM) –
+300 pM TCDF 53 pM (6.6 pM–430 pM) –
+100 pM PeCDF 31 pM (16 pM–61 pM) –
Human
TCDD 470 pM (340 pM–630 pM)**
+10 μM PCB 105b 17 nM (14 nM–20 nM)** 35-fold
+10 μM PCB 118b 11 nM (8.6 nM–14 nM)** 25-fold
+300 nM PCB 156 1.6 nM (410 pM–5.9 nM)* 3-fold
a Signiﬁcance indicates that the EC50 for TCDD with antagonist is statistically different
from TCDD alone in each species *(p b 0.01) and **(p b 0.001).
b No or limited measurable agonistic effect was detected so the maximum concentra-
tion based on the solubility of the compound was used.
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agonist in human.
4. Discussion
4.1. Mixed halogenated congeners
One of the main aims of this paper was to characterise the agonist
properties of several mixed halogenated AhR ligands based on their
ability to induce CYP1A1 RNA. REPs were calculated for most of the
compounds tested (Table 2). In rat H4IIE cells, TCDF and PCB 126 both
gave REPs of 0.1 and PeCDF gave a REP of 0.2 which corresponds well
with the TEFs calculated by the WHO consortium (van den Berg et al.,
2006) and shows reproducibility of results compared with thoseTable 4
Estimated REPs compared with TEFs.
Compound WHO 2005
TEFa
Estimated REP from this
studyb
Difference
2,3,7,8-TetraCDD 1 1 =
2-B,3,7,8-TriCDD 3 +3-fold
2,3-DiB-7,8-DiCDD 0.3 −3-fold
1,2,3,7,8-PentaCDD 1
1-B,2,3,7,8-TetraCDD 0.1 −10-fold
2-B,1,3,7,8-TetraCDD 0.3 −3-fold
2,3,7,8-TetraCDF 0.1 0.1 =
3-B,2,7,8-TriCDF 0.1 =
2,3-DiB,7,8-DiCDF 0.3 +3-fold
2,3,4,7,8-PentaCDF 0.3 0.3 =
4-B,2,3,7,8-TetraCDF 0.3 =
1,2,3,7,8-PentaCDF 0.03
1-B,2,3,7,8-TetraCDF 0.1 +3-fold
1,3,DiB,2,7,8-TriCDF 0.3 +10-fold
3,3′,4,4′,5-PentaCB 0.1 0.1 =
4′-B,3,3′,4,5-TetraCB 0.3 +3-fold
3′,4′-DiB,3,4,5-TriCB 0.1 =
3′,4′,5-TriB,3,4-DiCB 0.3 +3-fold
3,3′,4,4′,5-PentaBB 0.03 −3-fold
2,3,3′,4,4′-PentaCB 0.00003 0.000003 −10-fold
4′-B,2,3,3′,4-TetraCB 0.00001 −3-fold
2,3′,4,4′,5-PentaCB 0.00003 0.000003 −10-fold
4′-B,2,3′,4,5-TetraCB 0.00003 =
2,3,3′,4,4′,5-HexCB 0.00003 0.0003 +10-fold
4′-B,2,3,3′,4,5-PentaCB 0.0003 +10-fold
a TEFs from van den Berg et al., 2006.
b REP values from this study were rounded to the nearest half log unit to allow more
simplistic comparison with the TEFs.found in the literature. Mason et al. (1987) tested a small selection of
mixedhalogenated compounds in ratH4IIE cells producing EC50swithin
10-fold of this study although they found a much lower value for 2-
B,3,7,8-TriCDD than in this or other literature (Mason et al., 1987).
REPs identiﬁed for mixed halogenated compounds in this paper were
compared against values calculated in the literature (Table 2;
Behnisch et al., 2003;Olsman et al., 2007; Samara et al., 2009). However,
a key element of this experimental method was the robust design for
quantiﬁcation. The use of a 4 h induction periodwas crucial tominimise
the effect of P450 induction and degradation of the substance, thus
making it a much better measure of intrinsic agonism. Furthermore
the compounds used in this study were fully validated both to conﬁrm
concentration and to control for contaminants, allowing more conﬁ-
dence in the data obtained.
All of the REPs calculated for the mixed halogenated compounds
tested in this study were within 10-fold of their fully chlorinated coun-
terparts. Table 4 compares the REPs calculated in this paper with the
chlorinated congener with the same structure. A few compounds of no-
table potency were identiﬁed including 2-B,3,7,8-TriCDD which was
found to be 2- to 2.5-fold more potent than TCDD in both rat and
human cell lines. Also identiﬁed as very potent AhR agonists were 2-
B,1,3,7,8-TetraCDD and 2,3-DiB,7,8-DiCDF, which gave REPs of ~0.6
corresponding well with values found in the literature (Behnisch et al.,
2003; Olsman et al., 2007).
The addition of bromine had different effects on each of the three
groups of compounds. A bromine substitution on the dibenzo-p-dioxin
backbone skeleton reduced the potency of the compounds, with the
exception of 2-B,3,7,8-TriCDD. In contrast, the substitution of bromine
on the furan backbone skeleton increased the potency of the mixed ha-
logenated compounds. One suggestion for this would be that the furan
backbone is slightly smaller than the dibenzo-p-dioxin backbone skele-
ton as it only has one oxygen atom thus we propose that the increased
size of the bromine atomprovides a better ﬁt for the AhR ligand binding
domain. This also appears to be the same for themixed halogenated PXB
126 congeners, with the bromine making the molecule bigger and thus
potentially a better ﬁt for the AhR binding domain. Risk assessment of
mixtures containing PBB 126 uses the TEF for PCB 126, however, PBB
126 was found to be 3-fold less potent than PCB 126. The mono-ortho-
substituted PXBs were generally more potent than their chlorinated
congeners showing that the increased size of the compound allows it
to activate the AhR more effectively. There were signiﬁcant discrepan-
cies between the REPs calculated for PCB 105, PCB 118 and PCB 156 in
this paper and those calculated by the WHO consortium (van den
Berg et al., 2006). This work suggests that PCB 105 and PCB 118 were
10-fold less potent than previously estimated whereas PCB 156 was
10-fold more potent. The WHO consortium used a wide range of REPs,
derived using multiple endpoints and methodology, to estimate the
potency of each compound demonstrating the difﬁculty in concise TEF
calculation (Haws et al., 2006; van den Berg et al., 2006) and thus the
importance of using a quantitatively accurate method of measurement.
Additionally, differing measurement systems or contaminated stock
with more potent ligands may also produce differing potencies
(DeVito, 2003), one of the main reasons for verifying that the stocks
used in this study were uncontaminated.
4.2. Antagonistic effects of mono-ortho-PCBs
Several mono-ortho-substituted PCBs and PXBs were tested in rat
H4IIE cells and showed that all but PCB 156were partial agonists. A con-
centration of 1 μM PXB 105 was shown to reduce the potency of TCDD
by 200-fold showing that the compound is approximately a 20-fold
more potent antagonist than PCB 105. A concentration of 300 nM PXB
118 was shown to reduce the potency of TCDD by 3-fold making it
equivalent to PCB 118 in terms of antagonistic potential. PXB 156 was
shown to be a potent antagonist with a concentration of 100 nM PXB
156 reducing the potency of TCDD by 100-fold, whereas PCB156 had
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bromine atom had no effect on the agonistic properties of the com-
pound but it had a signiﬁcant effect on the antagonistic potential.
In human MCF-7 cells, PCB 118 and PCB 156 were shown to be par-
tial agonists whereas PCB 105 was shown to be a relatively potent an-
tagonist. A concentration of 3 μM PCB 105 in rat and 10 μM PCB 105 in
human reduced the potency of TCDD by ~30-fold. Further to this, a con-
centration of 3 μMPCB 118 in rat and 10 μMPCB 118 in human reduced
the potency of TCDD by 10- to 25-fold. Binding data for these com-
pounds is required to fully characterise their antagonistic properties.
PCB 156 was shown to have very weak antagonistic properties in
human and thus would have a very limited effect on the TEQ from an
antagonism perspective.
Based on these data, a number of environmentally important PCBs
have signiﬁcant antagonistic activity in both rat and human cells. All
of these compounds are present in the environment (Ahlborg et al.,
1992; Fernandes et al., 2004, 2008, 2014; Larebeke et al., 2001;
Kalantzi et al., 2004; Polder et al., 2008; Safe, 1990, 1994) and some
make substantial contributions to the total measurement of TEQ. There-
fore there might be signiﬁcant consequences for the normal TEF-based
method for deriving a TEQ, if the antagonistic effects of these com-
pounds were taken into account. Thus, it is important to develop meth-
odology to take these effects into account.
5. Conclusion
Most of the selected PXDDs tested in this study were found to have a
slightly lower potency than their fully chlorinated counterparts whereas
PXDFs and PXBswere shown to have a higher potency. It should however
be noted that the compounds tested in this study are only a fraction of the
total number of PXDD/Fs and PXBs therefore further testing would be re-
quired to fully qualify this observation. A new table of REPs has been pro-
duced for these compounds based on the data derived from this paper
which reﬂect their potency more accurately than the current TEFs for
chlorinated compounds. Recent research has shown the prevalence of
these compounds demonstrating the importance of accurate potency es-
timation for appropriate TEQ calculation. Fernandes et al. (2014) recently
reported the occurrence of PXDDs, PXDFs and PXBs, in comparison to the
chlorinated congeners, in a wide variety of common food items and
showed that inmost cases the addition ofmixed halogenated compounds
to the TEQ signiﬁcantly increased the contribution to dioxin-like toxicity.
This paper has also shown that PCB 105 and PCB 118 are partial
agonists, although they are essentially antagonists at all but the highest
of concentrations. The TEQ method assumes that all of the compounds
in the mixture are pure agonists and thus does not account for the an-
tagonistic properties of a compound. This study has demonstrated that
some of the compounds included in the TEQmethod are partial agonists
and decrease the ability of TCDD to induce CYP1A1. Consideration
should therefore be taken regarding the antagonistic properties of the
PCBs and PXBs in relation to their ability to reduce the potency of
other more potent AhR agonists.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.envint.2014.12.002.
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